FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

Cancer Chemotherapy and Pharmacology
Alberto ZaniboniRoberto Labianca

Abstract

The purpose of the present study was to evaluate the activity and the tolerability of the FOLFIRI regimen, administered as second-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer after the failure of a gemcitabine-based regimen. Patients with locally advanced/metastatic disease who received a first-line chemotherapy (one line only) with gemcitabine ± platinoid (cisplatin, oxaliplatin) and who had measurable disease conform with the RECIST criteria were eligible for the study. FOLFIRI consists of irinotecan 180 mg/m(2) i.v. on day 1, leucovorin (l-form) 200 mg/m(2) i.v. on day 1 and 2, 5-FU 400 mg/m(2) i.v. bolus on days 1 and 2, and 5-FU 600 mg/m(2) i.v. by ci for 22 h on days 1 and 2, repeated every 2 weeks. The primary end point was the response rate. Among the 50 enrolled patients, 4 partial responses (PR) (8%) and 14 stable diseases were observed, for a disease control rate of 18/50 (36%). Forty-one patients (82%) have been pretreated with cisplatin/oxaliplatin+gemcitabine as first-line chemotherapy. The median progression-free and overall survivals were 3.2 and 5 months, respectively. The 6-month survival rate was 32%. Grade 3-4 neutropenia and diarrhea occurred in 10 (20%) and 6 (12%) pa...Continue Reading

Associated Clinical Trials

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetUNKNOWN GISCAD
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Aug 2, 2007·Annals of Surgery·Karl Y BilimoriaMark S Talamonti
Oct 8, 2008·Cancer Chemotherapy and Pharmacology·Seong Yoon YiWon Ki Kang
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 18, 2009·Cancer Treatment Reviews·Ana CustodioEduardo Díaz-Rubio
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David CunninghamJohn P Neoptolemos
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe ColucciUNKNOWN Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
May 14, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Uwe PelzerHelmut Oettle
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew H Ko
Feb 7, 2012·American Journal of Clinical Oncology·Peter J HoseinCaio M Rocha Lima

❮ Previous
Next ❯

Citations

Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R LabiancaS Mosconi
Mar 8, 2014·World Journal of Gastroenterology : WJG·Evan J Walker, Andrew H Ko
Sep 2, 2015·Expert Review of Anticancer Therapy·Concetta Elisa OnestiPaolo Marchetti
Mar 27, 2015·Expert Opinion on Investigational Drugs·Edward J KimRichard J Bold
Oct 21, 2015·Critical Reviews in Oncology/hematology·Adnan M NagrialDesmond Yip
Feb 13, 2013·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Fa-Jun XieWenlin Huang
Dec 3, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Isabelle TrouilloudJulien Taïeb
Apr 1, 2015·Nature Reviews. Clinical Oncology·Ignacio Garrido-Laguna, Manuel Hidalgo
Dec 8, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Venkata V V R MaradaYohannes Hagos
Dec 31, 2014·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Manuel HidalgoVolker Heinemann
Jan 24, 2015·Scandinavian Journal of Gastroenterology·Mie GrunnetJan Stenvang
Jan 27, 2015·European Journal of Medicinal Chemistry·Venkata V V R MaradaYohannes Hagos
Sep 21, 2016·Cancer·Anna M VargheseEileen M O'Reilly
Sep 14, 2016·Journal of Oncology Practice·Gauri R Varadhachary, Robert A Wolff
Jun 21, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fausto PetrelliUNKNOWN GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) and Cremona Hospital
Mar 28, 2017·Therapeutic Advances in Medical Oncology·Emma KippsNaureen Starling
Jun 24, 2017·International Journal of Molecular Sciences·Aleksandra AdamskaMarco Falasca
Mar 23, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·David B ZhenVaibhav Sahai
Dec 1, 2017·The Cancer Journal·Andrew H Ko
Feb 11, 2016·World Journal of Clinical Oncology·Rosella SpadiMaria Antonietta Satolli
May 22, 2013·Molecular Pharmacology·Adam B RobertsMatthew R Redinbo
Apr 19, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·L Gutierrez-SainzJ Feliu
May 20, 2021·World Journal of Gastroenterology : WJG·Sara CherriAlberto Zaniboni
Nov 13, 2020·Visceral Medicine·Katrin Jana CiecielskiHana Algül

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volker HeinemannRalf Wilkowski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
David K ChangAndrew V Biankin
© 2021 Meta ULC. All rights reserved